Neuralstem Inc. (CUR)’s Financial Results Comparing With Novelion Therapeutics Inc. (NASDAQ:NVLN)

Neuralstem Inc. (NASDAQ:CUR) and Novelion Therapeutics Inc. (NASDAQ:NVLN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuralstem Inc. N/A 15.03 7.92M -0.52 0.00
Novelion Therapeutics Inc. 128.63M 0.18 113.47M -6.05 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Neuralstem Inc. and Novelion Therapeutics Inc.


Table 2 provides us the return on assets, return on equity and net margins of both companies.

Net Margins Return on Equity Return on Assets
Neuralstem Inc. 0.00% -123.1% -74.7%
Novelion Therapeutics Inc. -88.21% 404.3% -32.6%

Volatility & Risk

Neuralstem Inc.’s 1.84 beta indicates that its volatility is 84.00% more volatile than that of S&P 500. Novelion Therapeutics Inc.’s 1.64 beta is the reason why it is 64.00% more volatile than S&P 500.


The Current Ratio and a Quick Ratio of Neuralstem Inc. are 5.5 and 5.5. Competitively, Novelion Therapeutics Inc. has 0.2 and 0.2 for Current and Quick Ratio. Neuralstem Inc.’s better ability to pay short and long-term obligations than Novelion Therapeutics Inc.

Insider and Institutional Ownership

Neuralstem Inc. and Novelion Therapeutics Inc. has shares owned by institutional investors as follows: 6.3% and 76.5%. About 0.3% of Neuralstem Inc.’s share are owned by insiders. Competitively, insiders own roughly 0.7% of Novelion Therapeutics Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Neuralstem Inc. -14.71% -24.96% -62.7% -74.46% -80.85% -75.06%
Novelion Therapeutics Inc. 18.8% 63.05% -71.25% -71.39% -67.14% -63.14%

For the past year Neuralstem Inc. was more bearish than Novelion Therapeutics Inc.


Neuralstem Inc. beats Novelion Therapeutics Inc. on 5 of the 9 factors.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companyÂ’s stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.